ALLR Key Statistics, Chart & Performance
The current stock price of ALLR is 1.14 USD. In the past month the price decreased by -4.2%. In the past year, price increased by 11.76%.
ALLR Latest News, Press Relases and Analysis
ALLR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About ALLR
Company Profile
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Company Info
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Phone: 14014264664
ALLARITY THERAPEUTICS INC / ALLR FAQ
Can you describe the business of ALLARITY THERAPEUTICS INC?
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
What is the current price of ALLR stock?
The current stock price of ALLR is 1.14 USD. The price decreased by -0.87% in the last trading session.
Does ALLR stock pay dividends?
ALLR does not pay a dividend.
What is the ChartMill rating of ALLARITY THERAPEUTICS INC stock?
ALLR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ALLARITY THERAPEUTICS INC belong to?
ALLARITY THERAPEUTICS INC (ALLR) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ALLR stock?
ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 18.02M USD. This makes ALLR a Nano Cap stock.
ALLR Technical Analysis
ALLR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. The financial health of ALLR is average, but there are quite some concerns on its profitability.
ALLR Financial Highlights
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -123690. The EPS increased by 94.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.62% | ||
| ROE | -127.47% | ||
| Debt/Equity | 0 |
ALLR Forecast & Estimates
7 analysts have analysed ALLR and the average price target is 9.44 USD. This implies a price increase of 727.63% is expected in the next year compared to the current price of 1.14.